mct-23-0336_supplementary_figure_s7_supps7.docx (553.22 kB)
Supplementary Figure S7 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
journal contribution
posted on 2024-04-02, 07:20 authored by Ekta Patel, Natalia V. Malkova, David Crowe, Magali Pederzoli-Ribeil, Damiano Fantini, Manoussa Fanny, Hanumantha Rao Madala, Kurt A. Jenkins, Oleg Yerov, Justin Greene, Wilson Guzman, Caitlin O'Toole, Jacob Taylor, Rebekah K. O'Donnell, Parker Johnson, Bernard B. Lanter, Brian Ames, Jia Chen, Sallyann Vu, Hsin-Jung Wu, Susan Cantin, Megan McLaughlin, Yu-Shan S. Hsiao, Dheeraj S. Tomar, Raphael Rozenfeld, Lakshmanan Thiruneelakantapillai, Ronan C. O'Hagan, Benjamin Nicholson, Jennifer O'Neil, Carl Uli BialuchaSupplemental Figure S7: XTX301 caused transient and reversible changes to LFTs and other safety parameters in NHP in a repeat dose GLP toxicology study. Male and female NHPs (N=3/sex; 2/sex for recovery animals) were administered XTX301 by intravenous infusion once weekly for a total of four doses, followed by a four-week recovery period. Changes in (a) aspartate aminotransferase, (b) alanine aminotransferase, (c) total lymphocytes, (d) albumin, and (e) IFN- were fully reversible in the main study and recovery animals. All values are shown as mean ± SD. The reference ranges, indicated by the grey-shaded area, were derived from the study facility’s historical control values.